50th week of 2010 patent applcation highlights part 44 |
Patent application number | Title | Published |
20100317626 | The Use Of (3-Amino-2-Fluoropropyl) Phosphinic Acid For Treatment Of NERD - The present invention is directed to the use of (3-Amino-2-fluoropropyl)phosphinic acid or an optical isomer thereof, or a pharmaceutically acceptable salt thereof, for the treatment or prevention of non-erosive reflux disease (NERD). | 2010-12-16 |
20100317627 | Treatment of HCV Disorders - S1P receptor agonists are useful for the treatment of hepatitis C or chronic hepatitis C (HCV). | 2010-12-16 |
20100317628 | MicroRNA Modulators and Method for Identifying and Using the Same - The present invention is a method for identifying agents which modulate microRNA activity. The invention involves contacting a cell harboring a microRNA and a microRNA binding sequence, which is operably linked to a nucleic acid molecule encoding a reporter protein, with a test agent increases or decreases the expression of the reporter protein thereby identifying a microRNA modulator. Antagonists identified by this screening assay are provided, as are methods for using the same to inhibit microRNA activity and prevent or treat disease. | 2010-12-16 |
20100317629 | DISSOLVABLE PHARMACEUTICAL IMPLANT - A pharmaceutical implant may include a pharmaceutical and at least one excipient, and may be configured to be implanted in a body of a patient. The at least one excipient may dissolve after implantation of the pharmaceutical implant in the body of the patient and release the pharmaceutical. In some examples, the pharmaceutical implant includes at least two pharmaceuticals. The at least one excipient may be selected to provide a desired release profile of the pharmaceutical. For example, the pharmaceutical implant may be configured to dissolve and release the pharmaceutical over a length of time between about one day and about 30 days. In some examples, the pharmaceutical implant may be implanted in the body of the patient proximate to an implantable medical device. | 2010-12-16 |
20100317630 | NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS - The invention is directed to methods of using antagonists selective for the metabotropic mGlu5 receptor to treat conditions of neuromuscular dysfunction of the lower urinary tract in a mammal. Provided are methods of treating a mammal suffering from a condition of neuromuscular dysfunction of the lower urinary tract by administering a selective mGlu5 antagonist. The selective mGlu5 antagonist may be administered alone or in combination with one or more additional therapeutic agents for treating such a condition. Also provided are methods of identifying selective mGlu5 antagonists that are useful for treating neuromuscular dysfunction of the lower urinary tract in a mammal. Methods for treating migraine and gastroesophageal reflux disease (GERD) using selective mGlu5 antagonists are also disclosed. | 2010-12-16 |
20100317631 | Gel Composition and Transcrotal Application of a Composition for the Treatment of Hypogonadism - The present invention relates to a gel composition on alcoholic basis, comprising at least one androgenic steroid and at least one C | 2010-12-16 |
20100317632 | 17-(1'PROPENYL)-17-3'-OXIDOESTRA-4-EN-3-ONE DERIVATIVE, USE THEREOF, AND MEDICAMENT CONTAINING SAID DERIVATIVE - The invention relates to 17-(1′-propenyl)-17-3′-oxidoestra-4-en-3-one derivatives with the general chemical formula I, where the residues Z, R | 2010-12-16 |
20100317633 | HEXAHYDRO-CYCLOOCTYL PYRAZOLE CANNABINOID MODULATORS - This invention is directed to a hexahydro-cyclooctyl pyrazole cannabinoid modulator compound of formula (I): | 2010-12-16 |
20100317634 | PIPERIDYL-PROPANE-THIOL CCR3 MODULATORS - One object of the present invention are novel substituted piperidyl-propane-thiols of the formula (1), wherein R | 2010-12-16 |
20100317636 | REDUCING THE RISK OF CHRONIC LUNG DISEASE IN INFANTS - Described herein is a method for reducing the risk of chronic lung disease in an infant suffering from respiratory distress syndrome by administering to the infant a combination of a corticosteroid having a high local to systemic anti-inflammatory activity (e.g., budesonide) and a lung surfactant. | 2010-12-16 |
20100317637 | ANTI-HEPATITIS C COMPOSITION AND METHOD FOR PREPARING DRUG FOR INHIBITING HEPATITIS C VIRUSES OR TREATING HEPATITIS C - The invention provides an anti-hepatitis C composition including: an effective amount of limonoid compound, wherein the structure of the limonoid compound is shown as Structure (I): | 2010-12-16 |
20100317638 | Neuroactive 13,24-Cyclo-18,21-Dinorcholanes and Structurally Related Pentacylic Steroids - Novel pentacyclic steroids and pentacyclic D-homosteroids comprising: (i) the tetracyclic steroid ring system or tetracyclic D-homosteroid ring system, respectively; (ii) a C(3) substituent selected from the group consisting of (a) a hydroxyl or carboxyl in the α-configuration and (b) a sulfate or other negatively charged moiety; and (iii) a fused fifth ring, the fused fifth ring comprising a hydrogen bond acceptor, and (a) in the case of the pentacyclic steroid the C(13) and C(17) carbons, or (b) in the case of the pentacyclic D-homosteroid the C(13) and C(17a) carbons, having utility as anesthetics and in the treatment of disorders relating to GABA function and activity. | 2010-12-16 |
20100317639 | Medicament Based On a Monoester of Steroids With Long Chain Fatty Acids - A monoester of a family of steroids with a C | 2010-12-16 |
20100317640 | ANTIMICROBIAL ZINC PYRITHIONE COMPOSITION AND METHOD - The present invention relates to the field of antimicrobial formulations, and more specifically, to an antimicrobial formulation comprising zinc pyrithione in a stabilized dispersion. | 2010-12-16 |
20100317641 | THIAZOLES AND PYRAZOLES USEFUL AS KINASE INHIBITORS - The present invention relates to compounds useful as inhibitors of Aurora protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention. | 2010-12-16 |
20100317642 | PHARMACEUTICAL COMPOSITION OF ORLISTAT - A stable pharmaceutical composition comprising dispersion blend comprising 20 to 60% by weight of orlistat and 40% to 80% by weight of water soluble polymer carrier selected from hydroxypropyl methyl cellulose, methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose or hydroxypropyl methylcellulose and the like. | 2010-12-16 |
20100317643 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS - The invention provides compounds of Formula I, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, B, D, R | 2010-12-16 |
20100317644 | Substituted Sulfonamide Compounds - Substituted sulfonamide derivatives, a process for their preparation, pharmaceutical compositions containing these compounds, and to the use of substituted sulfonamide derivatives in the treatment or inhibition of pain and/or various disorders or disease states. | 2010-12-16 |
20100317645 | SUBSTITUTED DIAZEPINE SULFONAMIDES AS BOMBESIN RECEPTOR SUBTYPE-1 MODULATORS - Certain novel substituted diazepine sulfonamides are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes. | 2010-12-16 |
20100317646 | COMPOUNDS - A compound of formula I, or a pharmaceutically acceptable salt or ester thereof, | 2010-12-16 |
20100317647 | NOVEL CYCLOPENTANE DERIVATIVES - The invention relates to a compound of formula (I) | 2010-12-16 |
20100317648 | THERAPEUTIC COMPOUNDS - The invention provides a compound of formula I: | 2010-12-16 |
20100317649 | S1P Receptor Modulating Compounds and Use Thereof - The present invention relates to compounds that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. In certain embodiments, the compounds of the invention relate to aryl oxoimidazolidinyls. | 2010-12-16 |
20100317650 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS - The compounds of formula (I) | 2010-12-16 |
20100317651 | PYRAZINOOXAZEPINE DERIVATIVES - Provided is a compound having a serotonin 5-HT | 2010-12-16 |
20100317652 | Compounds Useful In Therapy - The present invention provides compounds of formula (I), | 2010-12-16 |
20100317653 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS - Compounds of formula (I), and salts and pro-drugs thereof: | 2010-12-16 |
20100317654 | 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL DERIVATIVES AND THEIR MEDICAL USE - This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors. | 2010-12-16 |
20100317655 | SULFONAMIDE INHIBITORS OF CARBONIC ANHYDRASE - The present invention relates to new sulfonamide inhibitors of carbonic anhydrase activity, pharmaceutical compositions thereof, and methods of use thereof. | 2010-12-16 |
20100317656 | IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS - Compounds of Formula (I): | 2010-12-16 |
20100317657 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES - The invention relates to the use of 1H-imidazo[4,5-c]quinolinone derivatives and salts thereof in the treatment of protein and/or lipid kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases; 1H-imidazo[4,5-c]quinolinone derivatives for use in the treatment of protein and/or lipid kinase dependent diseases; a method of treatment against said diseases, comprising administering the 1H-imidazo[4,5-c]quinolinone derivatives to a warm-blooded animal, especially a human; pharmaceutical preparations comprising an 1H-imidazo[4,5-c]quinolinone derivative, especially for the treatment of a protein and/or lipid kinase dependent disease; novel 1H-imidazo[4,5-c]quinolinone derivatives; and a process for the preparation of the novel 1H-imidazo[4,5-c]quinolinone derivatives. | 2010-12-16 |
20100317658 | 4,7-Dioxobenzothiazole-2-Carboxamide Derivatives, Their Preparation And Their Therapeutic Uses - A subject of the present invention is 4,7-dioxobenzothiazole-2-carboxamide derivatives, which inhibit the cdc25 phosphatases, in particular cdc25-C phosphatase. These compounds can in particular be used in the treatment of cancer. | 2010-12-16 |
20100317659 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF - Provided herein are quinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions. | 2010-12-16 |
20100317660 | Mediators of hedgehog signaling pathways, compositions and uses related thereto - The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist of formula (I) in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity. | 2010-12-16 |
20100317661 | SMALL MOLECULE INHIBITORS OF MDM2 AND THE USES THEREOF - The invention relates to small molecules which function as inhibitors of the interaction between p53 and MDM2. The invention also relates to the use of these compounds for inhibiting cell growth, inducing cell death, inducing cell cycle arrest and/or sensitizing cells to additional agent(s). | 2010-12-16 |
20100317662 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators - 286 - Compounds in accord with Formula I: | 2010-12-16 |
20100317663 | ANILINOPYRIDINES AS INHIBITORS OF FAK - The present invention relates to a compound of formula (I): | 2010-12-16 |
20100317664 | METHODS OF AFFECTING GASTROINTESTINAL TRANSIT AND GASTRIC EMPTYING, AND COMPOUNDS USEFUL THEREIN - Methods and compounds are disclosed for affecting gastrointestinal motility and gastric emptying, which comprise inhibiting tryptophan hydroxylase (TPH) in patients in need thereof | 2010-12-16 |
20100317665 | Anti-Inflammatory And Protein Kinase Inhibitor Compositions And Related Methods For Downregulation Of Detrimental Cellular Responses And Inhibition Of Cell Death - A novel class of pyridazine compositions and related methods of use. | 2010-12-16 |
20100317666 | Composition Comprising An NK-1 Receptor Antagonist And An SSRI For The Treatment Of Tinnitus And Hearing Loss - The present invention relates to methods for treating a subject suffering from tinnitus, hearing loss, or tinnitus and hearing loss comprising administering to the subject an effective amount of an NK1 receptor antagonist alone, or in combination with an effective amount of a selective serotonin reuptake inhibitor. Compositions and pharmaceutical formulations are also provided. | 2010-12-16 |
20100317667 | 1-aryl-or 1-heteroaryl-pyrido[B]indoles and uses thereof - Provided herein are 1-aryl or 1-heteroarylsubstituted phenanthrene diketo acid compounds. These compounds comprise a β-carboline ring structure substituted at C1 with an aryl or heteroaryl moiety and individually substituted at C3-C8 and N9 with a C | 2010-12-16 |
20100317668 | SUBSTITUTED PYRANO [2,3-B] PYRIDINAMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE - The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I | 2010-12-16 |
20100317669 | NOVEL SUBSTITUTED PIPERIDYL-PROPANE-THIOLS - One object of the present invention are novel substituted piperidyl-propane-thiols of the formula (1), wherein R | 2010-12-16 |
20100317670 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - The present invention discloses a compound of formula: | 2010-12-16 |
20100317671 | XANTHINE-BASED CYCLIC GMP-ENHANCING RHO-KINASE INHIBITOR INHIBITS PHYSIOLOGICAL ACTIVITIES OF LUNG EPITHELIAL CELL LINE - A pharmaceutical composition for a treatment of an interstitial lung disease is provided. The pharmaceutical composition comprises an effective amount of an active component being one selected from a group consisting of a KMUP compound, a KMUP monoquaternary ammonium salt and a KMUP monoquaternary ammonium complex salt, wherein the KMUP monoquaternary ammonium complex salt is synthesized by the KMUP compound and a carboxylic acid derivative of one selected from a group consisting of a statin, a non-steroid anti-inflammatory (NSAIDs) and an anti-asthmatic drug. | 2010-12-16 |
20100317672 | Monomaleate Monohydrate Salt of a 5HT1A Receptor Antagonist - The present invention relates to a monomaleate monohydrate salt of 7-methyl-6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4,5-dihydroimidazo[1,5-a]quinoline-3-carboxamide, uses of the salt as a medicament in the treatment of sexual dysfunction and pharmaceutical compositions and dosage forms comprising the salt. | 2010-12-16 |
20100317673 | N-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION - Compounds of formula (I): | 2010-12-16 |
20100317674 | Metabotropic Glutamate-Receptor-Potentiating Isoindolones - Compounds of formula I: | 2010-12-16 |
20100317675 | 6-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF - Compounds of formula (I): | 2010-12-16 |
20100317676 | Fused heterocyclic compounds, and compositions and uses thereof - Fused heterocyclic compounds are disclosed that have formula 1: | 2010-12-16 |
20100317677 | Methods of Treating a Microbial Infection by Modulating RNase-L Expression and/or Activity - The invention relates to methods and compositions for treating a microbial infection. In the present invention, RNase-L activity has been shown to play an integral role in innate immunity and for defense against invading microbes. The present invention is drawn to exploiting the role of RNase-L in innate immunity for methods of treating a microbial infection. The present invention is also drawn to exploiting the role of RNase-L in innate immunity for methods of treating an immune related disease or disorder. | 2010-12-16 |
20100317678 | HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE - Compounds of formula (I), and salts, N-oxides, hydrates and solvates thereof are histone deacetylase inhibitors and are useful in the treatment of cell proliferative diseases, including cancers: | 2010-12-16 |
20100317679 | SUBSTITUTED ARYL-FUSED SPIROCYCLIC AMINES - Substituted Aryl-fused Spirocyclic Amines of the formula (I): are provided, as are methods for their preparation and use. Such compounds may generally be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and therapeutic methods are provided, as are methods for using such ligands for detecting histamine H3 receptors (e.g., receptor localization studies). | 2010-12-16 |
20100317680 | PYRIMIDINE INHIBITORS OF KINASES - The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, | 2010-12-16 |
20100317681 | MODULATION OF SYSTEMIC EXPOSURE TO RIFAXIMIN - The present invention relates to the effect of hepatic insufficiency on the pharmacokinetics of rifaximin. Also provided are methods of determining an appropriate dose of rifaximin for a subject suffering from hepatic insufficiency. In addition, methods of treatment are provided subjects having or susceptible to hepatic insufficiency to be treated with rifaximin. | 2010-12-16 |
20100317683 | Preparation of 6-Alpha-Amino N-Substituted Morphinans by Catalytic Hydrogen Transfer - The present invention provides processes for the stereoselective synthesis of 6-alpha-amino N-substituted morphinans. In particular, the invention provides processes for the reductive amination of 6-keto N-substituted morphinans by catalytic hydrogen transfer. | 2010-12-16 |
20100317684 | Amide and Carbamate Derivatives of N-{2-[4-Amino-2- (Ethoxymethyl)-1H-Imidazo[4,5-c]Quinolin-1-Yl]-1,1-Dimethylethyl} Methanesulfonamide and Methods - Amide and carbamate derivatives N-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin- | 2010-12-16 |
20100317685 | N-PHENYL-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION - Compounds of formula (I): | 2010-12-16 |
20100317686 | N-HETEROCYCLIC-6-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF - Compounds of formula (I): | 2010-12-16 |
20100317687 | 2-BENZOYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - Compounds of formula (I) | 2010-12-16 |
20100317688 | 2-HETEROAROYLIMIDAZOL[1,2-a]PYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF - Compounds of formula (I): | 2010-12-16 |
20100317689 | Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety - The compounds of formulas (I), (II), (III) and (IV), where the symbols are as defined in the specification are prodrugs of proton pump inhibitors. The R | 2010-12-16 |
20100317690 | TREATMENT OF PROTEIN FOLDING DISORDERS - Described are various compounds and methods for the treatment of disorders arising from aberrant protein folding, including in particular lysosomal storage diseases. In particular, polyhydroxylated alkaloids and imino sugars which are pharmacoperones of an enzyme and which do not bind to a catalytic site of said enzyme are described. | 2010-12-16 |
20100317691 | ISOQUINOLONE COMPOUNDS AS SUBTYPE-SELECTIVE AGONISTS FOR MELATONIN RECEPTORS MT1 AND MT2 - A method of treating, preventing, or ameliorating a pathological condition associated with a melatonin receptor in a mammal by using a pharmaceutical composition containing a compound of formula (I) as a ligand interacting with the melatonin receptor, | 2010-12-16 |
20100317692 | Quinolone M1 Receptor Positive Allosteric Modulators - The present invention is directed to quinolone compounds of general formula (I) | 2010-12-16 |
20100317693 | 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE - To provide a compound which has a potent agonistic activity on GHS-R and which is useful as a therapeutic agent for systemic wasting diseases such as cachexia. | 2010-12-16 |
20100317694 | Solid pharmaceutical composition comprising donepezil hydrochloride - The invention relates to a solid pharmaceutical composition comprising donepezil hydrochloride hydrate and a process for its preparation. In particular it relates to a composition and a process wherein the donepezil hydrochloride retains its polymorphic form and is therefore highly stable against conversion into other polymorphic forms. | 2010-12-16 |
20100317695 | GEL COMPOSITION FOR TREATING MYCOSIS - The present invention aims to provide a gel composition for mycosis treatment, which ensures good absorption and permeation of (2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylenepiperidin-1-yl)-1-(1H-1,2,4-triazol-1-yl)-butan-2-ol into a target site (skin and nail). The present invention also aims to provide a gel composition for mycosis treatment, which is excellent in stability of this drug. | 2010-12-16 |
20100317696 | IMINOSUGARS AND METHODS OF TREATING BUNYAVIRAL AND TOGAVIRAL DISEASES - Provided are novel methods of treating and/or preventing a disease or condition caused by or associated with a virus belonging to the Bunyaviridae or Togaviridae family using iminosugars, such as DNJ derivatives. | 2010-12-16 |
20100317697 | Renin Inhibitors - Disclosed are compounds having the formula (I): wherein the R | 2010-12-16 |
20100317698 | Polysubstituted Pyridinylaminoalkylene- and Pyridinyloxyalkylene-Cyclopropanamine Compounds, a Process for Their Preparation and Pharmaceutical Compositions Containing Them - Compounds of formula (I): | 2010-12-16 |
20100317699 | USE OF HEDGEHOG AGONISTS IN THE TREATMENT OF MUSCULOSKELETAL-RELATED DISORDERS - The invention provides methods for the diagnosis and treatment of musculoskeletal disorders relating to the Hedgehog pathway, including but not limited to muscular dystrophy (e.g., Duchenne Muscular Dystrophy) using agents that agonize Sonic Hedgehog (shh), and thereby, the Hedgehog signaling pathway. Said agonizing agents include, e.g., the compounds of the invention (e.g., a compound of Formula I). The invention also provides methods of screening for agents that are capable of increasing the proliferation of muscle and/or muscle precursor cells. | 2010-12-16 |
20100317700 | PESTICIDAL COMPOSITIONS - To provide a formulation composition which improves the controlling effect of an anthranilamide compound against pests. A pesticide composition which is a concentrated composition containing an anthranilamide compound as a pesticidal active ingredient, a dispersant and a hydrophilic organic solvent, characterized in that when the composition is diluted with water, the anthranilamide compound precipitates as solid particles in water. | 2010-12-16 |
20100317701 | HETEROCYCLIC INHIBITORS OF NECROPTOSIS - The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-α) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I) and (Ia)-(Ie) and are shown to inhibit TNF-α induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring the compounds of the invention. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role. | 2010-12-16 |
20100317702 | CRYSTALLINE FORM OF FEBUXOSTAT - New forms of Febuxostat have been prepared and characterized. These forms are useful, for example, in the chronic management of hyperuricemia in patients with gout. | 2010-12-16 |
20100317703 | METHOD FOR INHIBITING BRASSININ OXIDASE - The present disclosure relates to a method for inhibiting brassinin oxidase comprising treating a pathogen that is producing BO with an effective amount of selected Paldoxin compounds. | 2010-12-16 |
20100317704 | SPIRO-CONDENSED IMIDAZOLONE DERIVATIVES INHIBITING THE GLYCINE TRANSPORTER - Compounds of formula (I) and salts thereof are provided: | 2010-12-16 |
20100317705 | Oligomer-Dantrolene Conjugates and Related Compounds - The invention relates to (among other things) oligomer-dantrolene conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered compounds. | 2010-12-16 |
20100317706 | HNF4alpha MODULATORS AND METHODS OF USE - Disclosed are methods and compositions relating to modulators, such as agonists and antagonists, of HNF4α. | 2010-12-16 |
20100317707 | Oligomer-Nitroimidazole Anti-Infective Conjugates - The invention provides (among other things) small molecule drugs that are chemically modified by covalent attachment of a water soluble oligomer. | 2010-12-16 |
20100317708 | CARCINOMA DIAGNOSIS AND TREATMENT, BASED ON ODC1 GENOTYPE - The present invention provides methods and kits a) for predicting colorectal cancer patient survival, as well as the survival of patients harboring other invasive cancers where cellular proliferation and carcinogenesis is linked, in part, to high levels of ODC activity and increased cellular polyamine contents, and b) for selecting the corresponding treatment options for such patients based on the allelic nucleotide sequence or SNP at position +316 of the ODC1 promoter gene as well as cancer treatment methods, in each case, which include the determination of the ODC1 promoter +316 position genotype, as a means to guide treatment selection. | 2010-12-16 |
20100317709 | SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR COMPOUNDS - The invention relates to compounds, in particular 2-amino-3,4,5,-trisubstituted thiophenes, pharmaceutical compositions containing them and the uses of said compounds and compositions for diseases related to sphingosine-1-phosphate (S1P) receptors, predominantly S1P3 receptors. The diseases include cardiovascular diseases, atherosclerosis, cancer, pulmonary oedema, autoimmune disorders and Adult Respiratory Distress Syndrome. | 2010-12-16 |
20100317710 | 3-(3-INDOLYL) PROPIONIC ACID CALCIUM SALT AND METHOD OF MAKING 3-(3-INDOLYL) PROPIONIC ACID FREE ACID THEREFROM - Substantially pure 3-(3-indolyl)propionic acid free acid is synthesized by converting the free acid to 3-(3-indolyl)propionic acid calcium salt (3-IPA calcium), precipitating and washing, and then reconverting the 3-IPA calcium to the free acid. 3-IPA calcium is suitable for use in pharmaceutical compositions in tablet and sustained-release dosage forms. 3-IPA calcium can be used to inhibit the cytotoxic effects of amyloid beta protein on cells, to treat fibrillogenic diseases in a mammal, and to treat diseases or conditions in which free radicals or oxidative stress plays a role. | 2010-12-16 |
20100317711 | STEM-LIKE CELLS AND METHOD FOR REPROGRAMMING ADULT MAMMALIAN SOMATIC CELLS - A new use is provided for small molecule inhibitors of Oct4 and Sox 2 as a cellular reprogramming agent and a method of reprogramming adult mammalian somatic cells into stem-like cells is provided, using small molecule inhibitors of Oct4 and Sox 2 without the need of any material derived from embryos or fetuses, and without the need of potentially harmful transfecting vectors. Stem-like cells created by the present invention can be induced to differentiate into terminally differentiated adult somatic cells, such as, for example, neuronal cells. | 2010-12-16 |
20100317712 | Estrogen Agonists/Antagonists For Preventing Breast Cancer - Compounds of this formula | 2010-12-16 |
20100317713 | MICRO-RNAS OF THE MIR-15 FAMILY MODULATE CARDIOMYOCYTE SURVIVAL AND CARDIAC REPAIR - A family of microRNAs, called the miR-15 family, which includes miR-195, are shown to be up-regulated during pathological cardiac remodeling and repress the expression of mRNAs required for cell proliferation and survival, with consequent loss of cardiomyocytes. Strategies to block expression of the miR-15 family in the heart as a treatment for diverse cardiac disease are provided. | 2010-12-16 |
20100317714 | COMPLEX MOLECULE INTERFERING THE EXPRESSION OF TARGET GENES AND ITS PREPARING METHODS - The present invention provides a complex molecule interfering the expression of target genes and the methods for preparing the complex molecule, wherein the complex molecule contains two siRNA strands X | 2010-12-16 |
20100317715 | METHODS FOR TREATING NEUROPSYCHIATRIC CONDITIONS - Provided herein are compositions and methods for treating a subject suffering from Fragile X syndrome, autism, Down's syndrome, mental retardation, or a neuropsychiatric condition (e.g., schizophrenia). The methods include systemic administration of a a therapeutically effective amount of a PAK inhibitor in combination with a Group I mGluR antagonist (e.g., an mGluR5 antagonist). The PAK inhibitor and mGluR antagonist can be administered together, e.g., in one pharmacological composition, or they can be administered separately. | 2010-12-16 |
20100317716 | RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) - This invention relates to compounds, compositions, and methods useful for modulating tumor necrosis factor and/or tumor necrosis factor receptor gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of tumor necrosis factor and/or tumor necrosis factor receptor gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of tumor necrosis factor and/or tumor necrosis factor receptor genes, (TNF and/or TNF receptor). | 2010-12-16 |
20100317717 | RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET DERIVED GROWTH FACTOR (PDGF) AND PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) - This invention relates to compounds, compositions, and methods useful for modulating platelet derived growth factor (PDGF) and/or platelet derived growth factor receptor (PDGFr) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of platelet derived growth factor (PDGF) and/or platelet derived growth factor receptor (PDGFr) gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of platelet derived growth factor (PDGF) and/or platelet derived growth factor receptor (PDGFr) genes, such as PDGF and/or PDGFr. | 2010-12-16 |
20100317718 | MODULATION OF HIF1 BETA EXPRESSION - Compounds, compositions and methods are provided for modulating the expression of HIF1-beta. The compositions comprise oligonucleotides, targeted to nucleic acid encoding HIF1-beta. Methods of using these compounds for modulation of HIF1-beta expression and for diagnosis and treatment of diseases and conditions associated with expression of HIF1-beta are provided. | 2010-12-16 |
20100317719 | Antisense Oligonucleotides (ODN) Against SMAD7 and Uses Thereof in Medical Field - The invention relates to antisense oligonucleotidic sequences (ODN) against Smad7 suitably modified, and their uses in medical field as therapeutic biological agents, in particular in the treatment of chronic inflammatory bowel disease, such as Crohn's disease and ulcerative colitis. | 2010-12-16 |
20100317720 | Methods and Compositions for the Treatment of Intestinal Conditions - Methods and compositions for the treatment of intestinal disorders, such as IBD and Crohn's disease, are disclosed. Preferred compositions include siNA. Also disclosed is a method of specifically targeting siNA to treat intestinal disorders by intrarectal administration of siNA compounds. | 2010-12-16 |
20100317721 | Compositions and Methods for Treating Tumors, Fibrosis, and Pulmonary Alveolar Proteinosis - The present disclosure provides pharmaceutical compositions and methods useful for modulating angiogenesis and for inhibiting metastasis, tumors, pulmonary alveolar proteinosis, and fibrosis in a mammalian tissue. Pharmaceutical compositions and methods include inhibitors of LOXL2 expression and activity, such as shRNA targeting LOXL2. | 2010-12-16 |
20100317722 | NUCLEIC ACID SEQUENCES COMPRISING NF-kB BINDING SITE WITHIN O(6)-METHYLGUANINE-DNA-METHYLTRANSFERASE (MGMT) PROMOTER REGION AND USES THEREOF FOR THE TREATMENT OF CANCER AND IMMUNE-RELATED DISORDERS - The invention relates to nucleic acid sequences comprising NF-κB binding sites derived from the MGMT promoter region and uses thereof as decoy molecules in the treatment of cancer and immune-related disorders. More particularly, the invention relates to nucleic acid sequences as well as to modified oligonucleotides (ODNs) comprising NF-κB binding sites derived from the MGMT promoter region, and uses thereof as decoy molecules for inhibiting NF-κB enhanced expression of MGMT. The invention further relates to compositions, kits and screening methods using the NF-κB binding sites of the invention or ODNs comprising the same for treating cancer and immune related disorders. | 2010-12-16 |
20100317723 | Nucleolin Specific Aptamer and Use thereof - Improved G-rich oligonucleotide (GRO) aptamers specific to nucleolin, a method of preparing the aptamers, and a use of the aptamers for diagnosing and/or treating a nucleolin-associated disease, are provided. | 2010-12-16 |
20100317724 | METHOD FOR SEARCHING FOR HOMING ENDONUCLEASES, THEIR GENES AND THEIR TARGETS - A computer implemented method for generating nucleotide sequences containing candidate homing endonuclease genes (HEGs). A search is performed in a database stored on a storage medium of nucleotide sequences for amino acid sequences having a subsequence having a homology level with the translation of a subsequence of one or more predetermined HEGs. For each amino acid sequence generated by the search, one or more nucleotide sequences are retrieved encoding the amino acid sequence. The results of this search used in a second search of a database stored on a storage medium to generate the HEG containing sequences. | 2010-12-16 |
20100317725 | Choline Esters - Compounds, formulations, and methods are provided containing the choline ester of a reducing agent, especially lipoic acid or derivatives thereof. The compounds may be administered via a topical ocular route to treat or prevent oxidative damage. | 2010-12-16 |
20100317726 | SLCO1B3 GENOTYPE - The invention relates methods of identifying and predicting inter-patient differences in prognostic prediction for survival in androgen independent prostate cancer. It further related to methods for determining and exploiting such differences to improve medical outcomes. Moreover, it provides methods for determining if a subject has prostate cancer. | 2010-12-16 |
20100317727 | ROSEMARY EXTRACTS, DIETARY AND PHARMACEUTICAL COMPOSTIONS CONTAINING THEM AND THEIR USES - The present invention refers to rosemary extracts for use as medicament for the treatment of a disorder connected to reduced neurotransmission, as well as to dietary and pharmaceutical compositions containing such rosemary extracts and their uses. | 2010-12-16 |